Sequential Dose-Dense Adjuvant Therapy With Doxorubicin, Paclitaxel, and Cyclophosphamide
|
|
- Moses Kennedy
- 5 years ago
- Views:
Transcription
1 Sequential Dose-Dense Adjuvant Therapy With Doxorubicin, Paclitaxel, and Cyclophosphamide Review Article [1] April 01, 1997 By Clifford A. Hudis, MD [2] The recognition of paclitaxel's (Taxol's) activity and non-cross-resistance with doxorubicin (Adriamycin) in the treatment of metastatic breast cancer has motivated study of the agent in the adjuvant setting. However, the ideal Introduction Despite the application of polychemotherapy, the majority of patients with node-positive early stage breast cancer ultimately experience relapse and die from their disease.[1] Two efforts that aim to increase the curative effect of systemic chemotherapy include increased dose-intensity and inclusion of non-cross- resistant drugs or regimens. Because of paclitaxel's (Taxol) activity and clinical non-cross-resistance with doxorubicin (Adriamycin) in the treatment of metastatic breast cancer, its use in the adjuvant setting is an exciting possibility.[2-5] However, the optimal means of incorporating this drug while maximizing the benefit of the other active agents remains unclear. One approach to applying combination chemotherapy is to simply coadminister two or more active drugs. When synergy occurs, this is a desirable strategy. Unfortunately, concurrent administration is more likely to be associated with increased toxicity than with synergy. Further, the usual strategy for coping with overlapping toxicities is to reduce the dose of the individual drugs. In the case of drugs with a steep dose-to-response relationship, dose reductions are especially undesirable, as they may reduce the effectiveness of the regimen. To avoid the problem of dose-limiting overlapping toxicities of agents given in combination, non-cross-resistant drugs can be given separately rather than concurrently. In the absence of synergistic cell kill, this is a reasonable approach. Various models have been used to plan the optimal delivery of non-cross-resistant regimens; however, it is the clinical result that should determine the best model for use in subsequent studies.[6-8] SEQUENTIAL THERAPY: THE MILAN MODEL An elegant trial from Milan is especially informative, because it compared the use of an alternating regimen with sequential administration. This seminal trial, now reported with a 10-year follow-up, confirmed the prediction of superiority for sequential therapy.[9] In this study, women with metastatic breast cancer, including women with four or more involved nodes, were treated with doxorubicin and cyclophosphamide/ methotrexate/5-fluorouracil (CMF) using one of two schedules: In the alternating-treatment arm, two cycles of CMF were delivered for every one of doxorubicin (symbolized as CCACCACCACCA). In the sequential-treatment arm, all four doses of doxorubicin were given first, followed by all eight doses of CMF (AAAACCCCCCCC).[10] Although it has been speculated that the early use of doxorubicin was responsible for the improved results seen in the sequential-treatment arm, a simpler explanation is that the benefits resulted from the greater dose intensity of doxorubicin achieved with the sequential-delivery approach.[7,11-13] To build on the exciting implications of this study, we performed a follow-up series of clinical trials (Table 1). DOSE-DENSE THERAPY Doxorubicin Followed by High-Dose Cyclophosphamide (A C) In an attempt to capitalize on the steep dose-to-response relationship associated with alkylating agents while incorporating the demonstrated benefits of sequential therapy, our group evaluated a regimen comprising doxorubicin (Adriamycin) followed by high-dose cyclophosphamide (A C). In this trial, cyclophosphamide 3,000 mg/m² was given intravenously for three cycles at 14-day intervals, replacing the 24-week regimen of CMF given every 21 days that was used in the earlier Page 1 of 5
2 Milan model. An earlier pilot study conducted in patients with advanced disease[14] prompted use of this dose and schedule of cyclophosphamide, given with G-CSF administered between cycles of cyclophosphamide to facilitate rapid recovery of peripheral blood counts and rapid retreatment. Radiation therapy and tamoxifen were given after chemotherapy in appropriate cases. In 74 patients with breast cancer and a median of nine involved nodes (range, four to 49), our pilot study demonstrated that such a regimen was not only feasible but also had a promising effect on relapse-free survival.[15] A prospective randomized Intergroup trial led by the Southwest Oncology Group is currently testing this treatment approach in patients with zero to three involved lymph nodes.[16] Sequential Therapy With Doxorubicin/Paclitaxel/ Cyclophosphamide (A T C) To maximize the potential benefit of paclitaxel as adjuvant therapy, we chose to incorporate the agent into our sequential dose-dense treatment plan with doxorubicin and cyclophosphamide. Given that every model of chemotherapy that assumes fractional cell kill predicts increased effectiveness with more frequent delivery of chemotherapy, we wanted both to shorten the intertreatment intervals between dosing of the three agents[17,18] and to exploit the dose-response relationship demonstrated for doxorubicin.[12] We therefore designed a regimen consisting of doxorubicin (Adriamycin) 90 mg/m², given every 14 days for three cycles, followed first by paclitaxel (Taxol) 250 mg/m² over 24 hours every 14 days for three cycles and then by cyclophosphamide 3,000 mg/m² every 14 days for three cycles (A T C). All nine cycles of chemotherapy were supported by G-CSF, with radiation therapy and tamoxifen as appropriate. The 42 patients treated had resectable breast cancer with a median of eight involved lymph nodes (range, four to 25). One patient developed disease progression while receiving doxorubicin and was taken off study before receiving paclitaxel and cyclophosphamide. Overall, 69% of the patients required hospitalization (usually for neutropenic fever), and 67% required transfusion of packed red blood cells. Platelet transfusion was required in 10%. Dose reductions of doxorubicin and paclitaxel were required in 10% and 20% of patients, respectively. Despite the extent of toxicity, relapse-free survival was impressive, with only three patients relapsing after just over 1 year of follow-up. We concluded that this regimen was feasible and worth further study, particularly in light of very promising relapse-free survival in patients who had undergone definitive local control surgery.[19] Previous successful delivery of two cycles of cyclophosphamide 3,000 mg/m² combined with paclitaxel 250 to 300 mg/m², given over 24 hours, suggested that combination of these drugs might be just as feasible as giving them purely by sequential administration.[20,21] Reasoning that we might then be able to treat patients in the adjuvant setting with all three agents over a shorter time period, while maintaining the dose-intensity of the sequential plan, we conducted a randomized phase II trial to prospectively compare the toxicity of this shorter regimen with sequential A T C. As before, treatment began with doxorubicin given every 14 days for three cycles, with G-CSF support. However, because the earlier trial required dose reductions of both doxorubicin and paclitaxel, we started with a lower doxorubicin dose of 80 mg/m². Then, by random assignment, patients were assigned to one of two treatment groups: Group A received paclitaxel 200 mg/m² over 24 hours for three cycles, followed by cyclophosphamide 3,000 mg/m² every 14 days for three cycles, again supported by G-CSF. Group B received three courses of combination treatment with both agents at the same dose levels. Thus, half of the patients had nine cycles of chemotherapy (doxorubicin followed by paclitaxel followed by cyclophosphamide), and half had only six (doxorubicin followed by combination paclitaxel/cyclophosphamide), but all received the same total dose of the three study agents. Although follow-up time is insufficient for comparison with previous studies, results of this study showed that the feasibility of the shorter six-cycle regimen was reduced in comparison to the longer, sequential-therapy regimen. Patients had significantly more dose delays, dose reductions, blood transfusions, and hospitalizations.[22] Based on results of this trial, we concluded that the nine-cycle, sequential regimen was preferable for further study. ONGOING STUDIES Paclitaxel Plus Doxorubicin Two European phase II trials[23,24] suggested that paclitaxel plus doxorubicin might provide Page 2 of 5
3 additive, if not synergistic, activity. A prospective randomized trial comparing the combination versus either drug alone has been completed but not yet published and promises to clarify the relative advantages and toxicities of the combination versus single-agent therapy with either drug.[25] To assess the value of this doxorubicin/paclitaxel couplet, and based on the exciting results of their phase II study, the group from Milan has begun a randomized trial to evaluate this combination as adjuvant or neoadjuvant therapy. Patients are randomly assigned to receive high-dose doxorubicin followed sequentially by CMF, similar to the regimen used in the earlier trial from Milan[9], or to receive lower-dose doxorubicin coupled with a 3-hour infusion of paclitaxel, a regimen that appears to be superior in phase II studies of patients with advanced disease. In this trial, patients also have been randomized for the timing of surgery and chemotherapy. Doxorubicin/Cyclophosphamide With or Without Paclitaxel An alternative means of adding paclitaxel that may avoid the potential for increased toxicity seen in some studies of concurrent dosing is delivery of paclitaxel following administration of the other agents. Two multicenter trials currently under way in the United States take this approach: The first study, led by the Cancer and Leukemia Group B but available through the Intergroup, randomizes patients to receive four courses of A C using standard, moderately increased, or markedly increased doses of doxorubicin. Subsequently, half of the patients receive paclitaxel and half do not. A second trial of similar design is being performed by the National Surgical Adjuvant Breast and Bowel Project. In this trial, four courses of standard A C are followed by four courses of paclitaxel, compared with four courses of standard A C without paclitaxel in women with resected node-positive breast cancer. Taken together, these two trials can be expected to determine the value of adding paclitaxel to A C as adjuvant chemotherapy for node-positive breast cancer.[16] FUTURE DIRECTIONS Currently, two prospective randomized trials are under way to test the benefits of high-dose autologous stem-cell_supported chemotherapy for patients with breast cancer involving 10 or more axillary lymph nodes.[16] To compare the efficacy and toxicity of sequential dose-dense therapy with A T C versus the more conventional dose-escalated approach, the Intergroup has begun a trial led by the Southwest Oncology Group (SWOG) in women with breast cancer and four to nine involved nodes. Eligible postoperative patients are randomized to treatment with sequential A T C as described above or to four cycles of A C followed by high-dose, autologous stem-cell-supported chemotherapy. Follow-up tamoxifen and radiotherapy are given as appropriate on both arms. Together with the two trials evaluating the simple addition of paclitaxel and the two trials evaluating high-dose chemotherapy, this study should help to further define the role of single-agent paclitaxel in the adjuvant setting and to clarify the relative benefits and toxicities of the dose-dense approach. References: 1. Anonymous: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 33 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15,71-85, Holmes F, Walters R, Theriault R, et al: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: , Reichman BS, Seidman AD, Crown JP, et al: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11: , Seidman A, Reichman B, Crown J, et al: Paclitaxel as second and subsequent therapy for metastatic breast cancer: Activity independent of prior anthracycline response. J Clin Oncol 13: , Gianni L, Munzone E, Capri G, et al: Paclitaxel in metastatic breast cancer: A trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 87: , Page 3 of 5
4 6. Goldie JH, Coldman AJ, Gudauskas GA: Rationale for the use of alternating non_cross-resistant chemotherapy. Cancer Treat Rep 66: , Day RS: Treatment sequencing, asymmetry, and uncertainty: Protocol strategies for combination chemotherapy. Cancer Res 46: , Norton L, Simon R: Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 61: , Norton L, Simon R: The Norton-Simon hypothesis revisited. Cancer Treat Rep 70: , Bonadonna G, Zambette M, Valagussa P: Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. JAMA 273: , Jones RB, Holland JF, Bhardwaj S, et al: A phase I-II study of intensive-dose Adriamycin for advanced breast cancer. J Clin Oncol 5: , Bronchud MH, Howell A, Crowther D, et al: The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer 60: , Wood W, Budman D, Korzun A, et al: Dose and dose intensity trial of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330: , Lichtman S, Ratain M, Van Echo D, et al: Phase I trial of granulocyte-macrophage colony-stimulating factor (GM-CSF) plus high dose biweekly cyclophosphamide: A CALGB study. J Natl Cancer Inst 85: , Hudis C, Lebwohl D, Crown J, et al: Adjuvant Therapy of Cancer IV, pp Philadelphia: Lippincott, Hudis C, Norton L: Adjuvant drug therapy for operable breast cancer. Semin Oncol 23: , Skipper HE: Kinetics of mammary tumor cell growth and implications for therapy. Cancer 28: , Norton L, Simon R, Brereton J, et al: Predicting the course of Gompertzian growth. Nature 264: , Hudis C, Seidman A, Baselga J, et al: Sequential adjuvant therapy with doxorubicin/ paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes. Semin Oncol 22(suppl 15):18-23, Fennelly D, Schneider J, Spriggs D, et al: Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses. J Clin Oncol 13: , Raptis G, Tiersten A, Fennelly D, et al: The addition of paclitaxel to high-dose cyclophosphamide and filgrastim markedly enhances the mobilization of CD 34+ peripheral blood progenitor cells in patients with responding metastatic breast cancer undergoing high-dose chemotherapy [Abstract]. Proc Am Soc Clin Oncol 14:313, Hudis C, Seidman A, Raptis G, et al: Sequential dose-dense doxorubicin paclitaxel cyclophosphamide is less toxic than doxorubicin concurrent paclitaxel + cyclophosphamide as adjuvant therapy in resected node positive breast cancer [Abstract]. Proc Am Soc Clin Oncol 15:119, Page 4 of 5
5 23. Gianni L, Munzone E, Capri G, et al: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13: , Dombernowsky P, Gehl J, Boesgaard M, et al: Treatment of metastatic breast cancer with paclitaxel and doxorubicin. Semin Oncol 22:13-17, Sledge GJ: Doxorubicin/paclitaxel combination chemotherapy for metastatic breast cancer: The Eastern Cooperative Oncology Group experience. Semin Oncol 22(suppl 12): , Source URL: in-paclitaxel-and-cyclophosphamide Links: [1] [2] Page 5 of 5
Adjuvant chemotherapy of breast cancer
Journal of BUON 10: 175-180, 2005 2005 Zerbinis Medical Publications. Printed in Greece REVIEW ARTICLE Adjuvant chemotherapy of breast cancer S. Bešlija Department of Medical Oncology, Institute of Oncology,
More informationPaclitaxel in Breast Cancer
Paclitaxel in Breast Cancer EDITH A. PEREZ Mayo Foundation and Mayo Clinic Jacksonville, Jacksonville, Florida, USA Key Words. Paclitaxel Antineoplastic agents Breast neoplasms Clinical trials ABSTRACT
More informationNeo-adjuvant and adjuvant treatment for HER-2+ breast cancer
Neo-adjuvant and adjuvant treatment for HER-2+ breast cancer Angelo Di Leo «Sandro Pitigliani» Medical Oncology Unit Hospital of Prato Istituto Toscano Tumori Prato, Italy NOAH: Phase III, Open-Label Trial
More informationChemotherapy of Breast Cancer
Japan - Taiwan Joint Symposium on Medical Oncology Session 7 Breast cancer journal homepage:www.cos.org.tw/web/index.asp Chemotherapy of Breast Cancer Mei-Ching Liu Department of Medicine, Koo Foundation
More informationKey Words. Adjuvant therapy Breast cancer Taxanes Anthracyclines
The Oncologist Mayo Clinic Hematology/Oncology Reviews Adjuvant Therapy for Breast Cancer: Recommendations for Management Based on Consensus Review and Recent Clinical Trials BETTY A. MINCEY, a,b FRANCES
More informationBreast cancer has the highest incidence among those
Medical Treatment of Breast Cancer Young Seon Hong, M.D. Department of Internal Medicine Catholic University of Korea, St. Mary's Hospital E mail : y331@cmc.cuk.ac.kr Abstract Breast cancer has the highest
More informationRelative dose intensity delivered to patients with early breast cancer: Canadian experience
M E D I C A L O N C O L O G Y Relative dose intensity delivered to patients with early breast cancer: Canadian experience S. Raza MD, S. Welch MD, and J. Younus MD ABSTRACT Adjuvant chemotherapy for early
More informationSequential Adriamycin and CMF in Metastatic Breast Cancer
Sequential Adriamycin and CMF in Metastatic Breast Cancer M. ZAMBETTI, A. GIACOBONE, M. TERENZIANI, P. ZUCCHINELLI, R. DEMICHELI, S. BIASI, P. PIOTTI, C. BARTOLI, P. VALAGUSSA, G. BONADONNA Istituto Nazionale
More informationTRANSPARENCY COMMITTEE OPINION. 15 February 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 February 2006 Taxotere 20 mg, concentrate and solvent for solution for infusion B/1 vial of Taxotere and 1 vial
More informationAdjuvant Systemic Therapy in Early Stage Breast Cancer
Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington
More informationTaxane/Anthracycline Combinations: Setting a New Standard in Breast Cancer?
Taxane/Anthracycline Combinations: Setting a New Standard in Breast Cancer? JEAN-MARC NABHOLTZ, ALESSANDRO RIVA University of California at Los Angeles, Jonsson Comprehensive Cancer Center at UCLA, Los
More informationCopyright, 1995, by the Massachusetts Medical Society
Copyright, 99, by the Massachusetts Medical Society Volume 332 APRIL 6, 99 Number ADJUVANT CYCLOPHOSPHAMIDE, METHOTREXATE, AND FLUOROURACIL IN NODE- POSITIVE BREAST CANCER The Results of Years of Follow-up
More informationClinical Expert Submission Template
Clinical Expert Submission Template Thank you for agreeing to give us a personal statement on your view of the technology and the way it should be used in the NHS. Health care professionals can provide
More informationUpdate from the 25th Annual San Antonio Breast Cancer Symposium December 11 14, 2002
Update from the 25th Annual San Antonio Breast Cancer Symposium December 11 14, 2002 Nearly 5,000 physicians, oncologists, radiologists, epidemiologists, basic scientists, and breast cancer advocates from
More informationVision of the Future: Capecitabine
Vision of the Future: Capecitabine CHRIS TWELVES Cancer Research Campaign Department of Medical Oncology, University of Glasgow, and Beatson Oncology Centre, Glasgow, United Kingdom Key Words. Capecitabine
More informationNadia Harbeck Breast Center University of Cologne, Germany
Evidence in Favor of Taxane Based Combinations and No Anthracycline in Adjuvant and Metastatic Settings Nadia Harbeck Breast Center University of Cologne, Germany Evidence in Favor of Taxane Based Combinations
More informationBristol-Myers Squibb Pharmaceuticals Ltd Taxol Early Breast Cancer SUBMISSION TO THE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
SUBMISSION TO THE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE TAXOL (PACLITAXEL) FOR THE ADJUVANT TREATMENT OF EARLY BREAST CANCER Page 1 of 86 Background The purpose of the background section
More informationComparative Study of Toxicity of Weekly versus Three -Weekly Regimen of Paclitaxel in Locally Advanced Breast Cancer
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 79-85, p-issn: 79-86.Volume 5, Issue Ver. IX (December. 6), PP 9-98 www.iosrjournals.org Comparative Study of Toxicity of Weekly versus Three
More informationDose Intensity for Breast Cancer
Review Article [1] June 01, 2001 By Deborah K. Armstrong, MD [2] and Nancy E. Davidson, MD [3] Despite nearly 20 years of study, the importance of chemotherapy dose intensity in breast cancer remains unclear.
More information30 TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS) NEW ADVANCES IN THE TREATMENT OF BREAST CANCER
EDUCATIONAL HIGHLIGHTS FROM DATA PRESENTED AT THE 30 TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS) NEW ADVANCES IN THE TREATMENT OF BREAST CANCER DECEMBER 13 16, 2007, SAN ANTONIO, TX, USA 2 CONTENTS
More informationEvolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Evolving Insights into Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic
More informationADVANCES IN the adjuvant chemotherapy of primary,
Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node- Positive Primary Breast Cancer: First
More informationActivity of Combination Chemotherapy, Docetaxel and Epirubicin as Neoadjuvant Therapy for Women with Breast Cancer
Activity of Combination Chemotherapy, Docetaxel and Epirubicin as Neoadjuvant Therapy for Women with Breast Cancer ARAFAT TFAYLI 1, JENNIFER HOLTER 1, ABBY BOVA 1, SIDDHARTHA VENKATAPPA 2, SUSIE BULLOCK
More informationPostoperative Adjuvant Chemotherapies. Stefan Aebi Luzerner Kantonsspital
Postoperative Adjuvant Chemotherapies Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Does Chemotherapy Work in Older Patients? ER : Chemotherapy vs nil Age
More informationTreatment of HER-2 positive breast cancer
EJC SUPPLEMENTS 6 (2008) 21 25 available at www.sciencedirect.com journal homepage: www.ejconline.com Treatment of HER-2 positive breast cancer Matteo Clavarezza, Marco Venturini * Ospedale Sacro Cuore
More informationConsiderations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Considerations in Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic Treatment
More informationStrategies of Radiotherapy for Intermediate- to High-Risk Prostate Cancer
Strategies of Radiotherapy for Intermediate- to High-Risk Prostate Cancer Daisaku Hirano, MD Department of Urology Higashi- matsuyama Municipal Hospital, Higashi- matsuyama- city, Saitama- prefecture,
More information新竹馬偕紀念醫院癌症中心 乳癌化學治療藥物處方
新竹馬偕紀念醫院癌症中心 乳癌化學治療藥物處方 文件修訂記錄 修正次數 修正日期 修正版別 修 改 內 容 1 2011.04.07 1.0 初次訂定 2 2013.05.08 2.0 修訂 3 2013.04.30 3.0 修訂 :Triple-Negative Breast Cancer 處方 新增 :Neoadjuvant-p7~8 4 2014.04.29 4.0 修訂 :FEC + Trastuzumab
More informationOriginal article. The impact of Filgrastim schedule variation on hematopoietic recovery post-chemotherapy
Annals ofoncology 8: 7-24, 997. O 997 Kluwer Academic Publishers. Printed in the Netherlands. Original article The impact of Filgrastim schedule variation on hematopoietic recovery post-chemotherapy J.
More informationNCCP Chemotherapy Regimen. Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (80) 7 day Therapy (DD AC-T)
Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (80) 7 day Therapy (DD AC-T) INDICATIONS FOR USE: INDICATION Adjuvant Treatment of High Risk Node Negative or Node Positive
More informationOncologist. The. Docetaxel and Paclitaxel in the Treatment of Breast Cancer: A Review of Clinical Experience
The Oncologist Docetaxel and Paclitaxel in the Treatment of Breast Cancer: A Review of Clinical Experience JOHN CROWN, MICHAEL O LEARY, WEI-SEONG OOI St. Vincent s University Hospital, Dublin, Ireland
More informationBreast Cancer Breast Managed Clinical Network
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Less than 4 positive lymph nodes Adjuvant Treatment ER Positive HER2 Negative (see page 2 & 3 ) HER2 Positive
More informationThe absolute benefit from chemotherapy for both older and younger patients appeared most significant in ER-negative populations.
Hello, my name is Diane Hecht, and I am a Clinical Pharmacy Specialist at the University of Texas MD Anderson Cancer Center. It s my pleasure to talk to you today about the role of chemotherapy in this
More informationBreast Cancer? Breast cancer is the most common. What s New in. Janet s Case
Focus on CME at The University of Calgary What s New in Breast Cancer? Theresa Trotter, MD, FRCPC Breast cancer is the most common malignancy affecting women in Canada, accounting for almost a third of
More informationPERJETA (pertuzumab) FOR TREATMENT OF MALIGNANCIES
PERJETA (pertuzumab) FOR TREATMENT OF MALIGNANCIES Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures,
More informationTreatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic Therapy
Women s Empowerment Cancer Advocacy Network (WE CAN) Conference Bucharest, Romania October 2015 Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic
More informationJonathan Dickinson, LCL Xeloda
Xeloda A blockbuster in the making Jonathan Dickinson, LCL Xeloda Xeloda unique tumor-activated mechanism Delivering more cancer-killing agent straight into cancer Highly effective comparable efficacy
More informationBreast Cancer. Controversies in the Therapy of Early Stage Breast Cancer. The Oncologist 2005;10:
This material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com Breast Cancer Controversies in the Therapy of Early Stage Breast
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Cortazar P, Zhang L, Untch M, et al. Pathological
More informationNCCP Chemotherapy Regimen
Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH) Note: There is an option for Dose Dense DOXOrubicin, cyclophosphamide
More informationDennis J Slamon, MD, PhD
I N T E R V I E W Dennis J Slamon, MD, PhD Dr Slamon is Professor of Medicine, Chief of the Division of Hematology/Oncology and Director of Clinical and Translational Research at UCLA s David Geffen School
More informationNCCP Chemotherapy Regimen. Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLItaxel (175) 14 day Therapy (DD AC-T)
Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLItaxel (175) 14 day Therapy (DD AC-T) Note: There is an option for DOXOrubicin, cyclophosphamide followed by weekly PACLItaxel
More informationAdjuvant Chemotherapy for Elderly Women with Breast Cancer: Matti S. Aapro, M.D. IMO Clinique de Genolier Switzerland
SIOG Berlin October 2009 Adjuvant Chemotherapy for Elderly Women with Breast Cancer: Immediate Benefit and Long-Term Risk Matti S. Aapro, M.D. IMO Clinique de Genolier Switzerland 1 2 BACKGROUND MESSAGE
More informationAmerican Society of Clinical Oncology June , New Orleans
American Society of Clinical Oncology June 5-8 2004, New Orleans The 2004 annual meeting of the American Society of Clinical Oncology (ASCO) was held June 5 8 in New Orleans, Louisiana. This conference
More informationAdjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009
HIGHLIGHT ARTICLE - Slide Show Adjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009 Muhammad Wasif Saif
More informationPhase 1 Trial of Ifosfamide and Adriamycin in Metastatic Breast Cancer
Phase 1 Trial of Ifosfamide and Adriamycin in Metastatic Breast Cancer Z. Aziz,S. Sana,M. Akram ( Department of Oncology, Allama Iqbal Medical College, Lahore. ) N. Ilyas ( INMOL Hospital, Lahore. ) Abstract
More informationSymposium article. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data
Annals of Oncology 12 (Suppl. I): S57-S62, 2001. 2001 Kluwer Academic Publishers. Primed in the Netherlands. Symposium article Trastuzumab combined with chemotherapy for the treatment of HER2-positive
More informationIs Breast Radiation Therapy Necessary in the Elderly? Cancer and Leukemia Group B Radiation Therapy Oncology Group Eastern Cooperative Oncology Group
Is Breast Radiation Therapy Necessary in the Elderly? Cancer and Leukemia Group B Radiation Therapy Oncology Group Eastern Cooperative Oncology Group CALGB 9343 Submitted 1990 Opened July 15, 1994 Closed
More informationRADIATION THERAPY WITH ONCE-WEEKLY GEMCITABINE IN PANCREATIC CANCER: CURRENT STATUS OF CLINICAL TRIALS
doi:10.1016/s0360-3016(03)00449-8 Int. J. Radiation Oncology Biol. Phys., Vol. 56, No. 4, Supplement, pp. 10 15, 2003 Copyright 2003 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/03/$
More informationNCCP Chemotherapy Regimen
DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) Note: There is an option for Dose Dense DOXOrubicin, cyclophosphamide PACLitaxel (DD AC T) therapy described
More informationDocetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.
Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled
More informationtrial update clinical
trial update clinical by John W. Mucenski, BS, PharmD, Director of Pharmacy Operations, UPMC Cancer Centers The treatment outcome for patients with relapsed or refractory cervical carcinoma remains dismal.
More informationAdjuvant therapies for large bowel cancer Wasantha Rathnayake, MD
LEADING ARTICLE Adjuvant therapies for large bowel cancer Wasantha Rathnayake, MD Consultant Clinical Oncologist, National Cancer Institute, Maharagama, Sri Lanka. Key words: Large bowel; Cancer; Adjuvant
More informationHigh-dose sequential chemotherapy with stem cell support for non-metastatic breast cancer
Bone Marrow Transplantation, (1997) 20, 199 203 1997 Stockton Press All rights reserved 0268 3369/97 $12.00 High-dose sequential chemotherapy with stem cell support for non-metastatic breast cancer P Viens
More informationSustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA
Sustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA The fascinating history of Herceptin 1981 1985 1987 1990 1992 1998 2000 2005 2006 2008 2011 Murine
More informationBreast cancer remains the most common malignancy and the second leading. cause of cancer mortality in women in the United States.
Dr. Andrew Seidman s Commentary I. Breast Cancer Overview Breast cancer remains the most common malignancy and the second leading cause of cancer mortality in women in the United States. The following
More informationCOME HOME Innovative Oncology Business Solutions, Inc.
Innovative Oncology Business Solutions, Inc. Breast Cancer Diagnostic/Therapeutic Pathway V11, April 2015 Required Structured Data Fields: ICD9 Code Stage Staging Components Performance Status Treatment
More information亞東紀念醫院 Breast Cancer 化學治療處方集
亞東紀念醫院 Breast Cancer 化學治療處方集 2008-08 制定 最近修改日期 :2015-01 CMF Breast cancer 化學治療處方參考集 Adjuvant Classic CMF Cyclophosphamide 100mg/m2 PO qd; D1-D14 Methotrexate 40mg/m 2 in N/S 100 ml IV drip 30 mins; D1,
More informationWeekly Paclitaxel for Metastatic Breast Cancer in Patients Previously Exposed to Paclitaxel
www.journalofcancerology.com PERMANYER J Cancerol. 0;:-9 JOURNAL OF CANCEROLOGY CLINICAL CASE Weekly Paclitaxel for Metastatic Breast Cancer in Patients Previously Exposed to Paclitaxel Benjamín Dávalos-Félix,
More informationNorthwestern Memorial Hospital, Chicago, Illinois, and *St Jude Children s Research Hospital, Memphis, Tennessee, USA
Review Molecular biology of breast cancer metastasis The use of mathematical models to determine relapse and to predict response to chemotherapy in breast cancer Susan E Clare, Faina Nakhlis and John Carl
More informationOPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER. Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx
OPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx ANTHRACYCLINES AND TAXANES ARE COMMONLY USED USED IN MOST REGIMENS
More informationJ 13 (10) : , 1995 STUDY DESIGN AND CONDUCT
High-Dose Chemotherapy With Hematopoietic Rescue as Primary Treatment for Metastatic Breast Cancer: A Randomized Trial. Bezwoda WR, Seymour L and Dansey RD. J Clin Oncology, 13 (10) : 2483-2489, Oct 1995
More informationSTUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER
Contact: Anne Bancillon + 33 (0)6 70 93 75 28 STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Key results of 42 nd annual meeting of the American Society of Clinical
More informationSesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015
Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant
More informationClinical Impact of primary prophylaxis for FN in breast cancer patients. Prof. Young Jin Suh The Catholic University of Korea
Clinical Impact of primary prophylaxis for FN in breast cancer patients Prof. Young Jin Suh The Catholic University of Korea Objectives Describe the prevalence of febrile neutropenia in patients with breast
More informationReview Recent advances in systemic therapy Advances in adjuvant systemic chemotherapy of early breast cancer Sara López-Tarruella and Miguel Martín
Review Recent advances in systemic therapy Advances in adjuvant systemic chemotherapy of early breast cancer Sara López-Tarruella and Miguel Martín Medical Oncology Department, Clínico San Carlos Hospital,
More informationSystemic Therapy Considerations in Inflammatory Breast Cancer
Systemic Therapy Considerations in Inflammatory Breast Cancer Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel Disclosures Roche: Speakers bureau,
More informationAdjuvant Chemotherapy + Trastuzumab
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Adjuvant Chemotherapy + Trastuzumab (Optimal Drugs / Dosage / Trastuzumab) Adjuvant Chemotherapy (Optimal Drugs / Optimal Dosage
More informationUse of Taxanes in Older Breast Cancer Patients
SIOG Guidelines Update 2014: Use of Taxanes in Older Breast Cancer Patients Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Fundamental steps Task Force (TF) on
More informationMdi Medical Management of Breast Cancer Morbidity and Mortality Aug 13, 2009 Irina Kovatch, PGY3 Introduction Metastatic disease is the principal cause of death from breast cancer Metastatic events often
More informationCorporate Medical Policy
White Blood Cell Growth Factors Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: white_blood_cell_growth_factors 9/2016 4/2017 4/2018 6/2017 Description of
More informationCurrent Status of Adjuvant Therapy for Colorectal Cancer
Review Article [1] May 01, 2004 By Michael J. O connell, MD [2] Adjuvant therapy with chemotherapy and/or radiation therapy in addition to surgery improves outcome for patients with high-risk carcinomas
More informationIt is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast
More informationAppendix 2. Adjuvant Regimens. AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2
Appendix 2 Adjuvant Regimens AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2 CMF IV cyclophosphamide 600 mg/m 2 days 1 & 8 every 4 weeks methotrexate 40 mg/m 2 for 6 cycles
More informationFDA APPROVES HERCEPTIN FOR THE ADJUVANT TREATMENT OF HER2-POSITIVE NODE-POSITIVE BREAST CANCER
NEWS RELEASE Media Contact: Kimberly Ocampo (650) 467-0679 Investor Contact: Sue Morris (650) 225-6523 Advocacy Contact: Ajanta Horan (650) 467-1741 FDA APPROVES HERCEPTIN FOR THE ADJUVANT TREATMENT OF
More informationBRLAACDT. Protocol Code. Breast. Tumour Group. Dr. Karen Gelmon. Contact Physician
BCCA Protocol Summary for Treatment of Locally Advanced Breast Cancer using DOXOrubicin and Cyclophosphamide followed by DOCEtaxel and Trastuzumab (HERCEPTIN) Protocol Code Tumour Group Contact Physician
More informationHematopoietic Growth Factors* Defining the Appropriate Clinical Role in Multimodality Cancer Therapy
Hematopoietic Growth Factors* Defining the Appropriate Clinical Role in Multimodality Cancer Therapy George D. Demetri, MD Laboratory investigations have begun to elucidate the regulatory molecules that
More informationSYSTEMIC TREATMENT OF TRIPLE NEGATIVE BREAST CANCER
SYSTEMIC TREATMENT OF TRIPLE NEGATIVE BREAST CANCER Sunil Shrestha 1*, Ji Yuan Yang, Li Shuang and Deepika Dhakal Clinical School of Medicine, Yangtze University, Jingzhou, Hubei Province, PR. China Department
More informationFEC-T plus trastuzumab & pertuzumab
Page 1 of 5 Indication Treatment Intent Frequency and number of cycles Monitoring parameters pre-treatment The neoadjuvant treatment of locally advanced, inflammatory or early HER2 positive breast cancer
More informationNational Horizon Scanning Centre. Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy
Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy December 2007 This technology summary is based on information available at the time of research and
More informationAdjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group Randomized Trial
JNCI Journal of the National Cancer Institute Advance Access published January 8, 2008 ARTICLE Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group
More informationBreast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital
Breast Cancer Earlier Disease Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Switzerland Breast Cancer Earlier Disease Diagnosis and Prognosis Local Therapy Surgery Radiation therapy Adjuvant
More informationSan Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy
San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy Kathleen C. Horst, M.D. Assistant Professor Department of Radiation Oncology Stanford University The Optimal SEquencing of Adjuvant Chemotherapy
More informationNCCP Chemotherapy Regimen. DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)
DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH) Note: There is an option for Dose Dense DOXOrubicin, cyclophosphamide PACLitaxel
More informationPreventing Neutropenic Complications
Preventing Neutropenic Complications Michael Rader, MD Clinical Assistant Professor of Medicine, Columbia University College of Physicians and Surgeons Director, Union State Bank Cancer Center at Nyack
More informationA phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008
A phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008 NCT02432365 Chyong-Huey Lai, MD On behalf of Principal investigator
More informationPolicy No: dru281. Medication Policy Manual. Date of Origin: September 24, Topic: Perjeta, pertuzumab. Next Review Date: May 2015
Medication Policy Manual Topic: Perjeta, pertuzumab Committee Approval Date: May 9, 2014 Policy No: dru281 Date of Origin: September 24, 2012 Next Review Date: May 2015 Effective Date: June 1, 2014 IMPORTANT
More informationBRAJACTT. Protocol Code. Breast. Tumour Group. Dr. Karen Gelmon. Contact Physician
BC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer using DOXOrubicin and Cyclophosphamide followed by PACLitaxel and Trastuzumab (HERCEPTIN) Protocol Code Tumour Group Contact Physician
More informationBCCA Protocol Summary for Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin and Cyclophosphamide and DOCEtaxel
BCCA Protocol Summary for Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin Cyclophosphamide DOCEtaxel Protocol Code Tumour Group Contact Physician BRAJFECD Breast Dr. Stephen Chia ELIGIBILITY:
More informationBCCA Protocol Summary for Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin and Cyclophosphamide
BCCA Protocol Summary for Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin Cyclophosphamide Protocol Code Tumour Group Contact Physician BRAJFEC Breast Dr. Susan Ellard ELIGIBILITY: Patients
More informationVinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II trial
Original article Annals of Oncology 14: 699 703, 2003 DOI: 10.1093/annonc/mdg199 Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II
More informationTITLE: HER2/neu Antisense Therapeutics in Human Breast Cancer. CONTRACTING ORGANIZATION: Washington University School of Medicine St.
AD Award Number: DAMD17-99-1-9436 TITLE: HER2/neu Antisense Therapeutics in Human Breast Cancer PRINCIPAL INVESTIGATOR: Jeffrey A. Drebin, M.D., Ph.D. CONTRACTING ORGANIZATION: Washington University School
More informationCommon disease 175,000 new cases/year 44,000 deaths/year Less than 10% with newly diagnosed at presentation have stage IV disease Chronic disease,
Chemotherapy for Metastatic Breast Cancer: Recent Results HARMESH R. NAIK, MD. Karmanos Cancer Institute and St. Mary Hospital Metastatic breast cancer (MBC) Common disease 175,000 new cases/year 44,000
More informationCombined chemotherapy and Radiotherapy for Patients with Breast Cancer and Extensive Nodal Involvement.
Combined chemotherapy and Radiotherapy for Patients with Breast Cancer and Extensive Nodal Involvement. Ung O, Langlands A, Barraclough B, Boyages J. J Clin Oncology 13(2) : 435-443, Feb 1995 STUDY DESIGN
More informationTable S2. Expression of PRMT7 in clinical breast carcinoma samples
Table S2. Expression of PRMT7 in clinical breast carcinoma samples (All data were obtained from cancer microarray database Oncomine.) Analysis type* Analysis Class(number sampels) 1 2 3 4 Correlation (up/down)#
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationToxicities of Chemotherapy Regimens used in Early Breast Cancer
Toxicities of Chemotherapy Regimens used in Early Breast Cancer CERCIT Workshop February 17, 2012 Carlos H Barcenas, M.D., M.S. Fellow Hematology-Oncology MD Anderson Cancer Center CERCIT Scholar Outline
More informationDRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Guidance for Industry Pathologic Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval DRAFT GUIDANCE This guidance document
More informationCancer Treatments Subcommittee of PTAC meeting held 20 August. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC meeting held 20 August 2010 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationUpdate on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer
Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy NACT in Cervical Cancer NACT Stage -IB2 -IIA>4cm
More information